Lung Cancer

There has been a “renaissance” in the treatment strategies of patients with non-small cell lung cancer (NSCLC) who have EGFR-mutation–positive disease, Edward S. Kim, M.D.

Clinical trials of combination immunotherapy treatments are showing impressive overall survival rates.

Alecensa (alectinib) was granted approval by the Food and Drug Administration (FDA) to treat patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.

More patients with non-small cell lung cancer (NSCLC) should be evaluated and referred to clinical trials, especially those who may have molecular abnormalities, says Victoria M. Villaflor, M.D.

After a shocking diagnosis, Heather Von St. James is on a mission to spread awareness about mesothelioma.

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer (SCLC) and mesothelioma, two aggressive thoracic malignancies with few options.

Sometimes patients with cancer need to adjust their thinking to change how they view their disease

Question: When do cancer scans shift from disease monitoring to routine checkups? Answer: You decide.

The approval is based on data from the phase 3 CheckMate-057 trial, in which second-line Opdivo reduced the risk of death by 28 percent versus docetaxel in patients with nonsquamous NSCLC.